Equities Analysts Offer Predictions for ATXS FY2026 Earnings

Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Astria Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the biotechnology company will earn ($2.59) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $47.00 price target on the stock. The consensus estimate for Astria Therapeutics' current full-year earnings is ($1.65) per share.

Other equities research analysts also recently issued research reports about the company. Wedbush reaffirmed an "outperform" rating and issued a $28.00 target price (up previously from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Tuesday, March 11th. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Astria Therapeutics has an average rating of "Buy" and an average target price of $30.00.

Astria Therapeutics Stock Up 1.4%

Shares of ATXS stock traded up $0.08 during trading hours on Tuesday, reaching $5.79. The company's stock had a trading volume of 363,816 shares, compared to its average volume of 373,263. The firm's 50 day simple moving average is $4.55 and its 200-day simple moving average is $6.65. The company has a market capitalization of $326.75 million, a price-to-earnings ratio of -2.77 and a beta of 0.39. Astria Therapeutics has a fifty-two week low of $3.56 and a fifty-two week high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.10).

Institutional Investors Weigh In On Astria Therapeutics

Several hedge funds have recently modified their holdings of the company. Jane Street Group LLC boosted its holdings in shares of Astria Therapeutics by 317.3% during the 1st quarter. Jane Street Group LLC now owns 108,898 shares of the biotechnology company's stock valued at $582,000 after acquiring an additional 82,805 shares in the last quarter. ADAR1 Capital Management LLC boosted its holdings in shares of Astria Therapeutics by 605.3% during the 1st quarter. ADAR1 Capital Management LLC now owns 641,690 shares of the biotechnology company's stock valued at $3,427,000 after acquiring an additional 550,706 shares in the last quarter. PDT Partners LLC raised its position in Astria Therapeutics by 173.2% during the 1st quarter. PDT Partners LLC now owns 28,707 shares of the biotechnology company's stock worth $153,000 after purchasing an additional 18,200 shares during the last quarter. Cubist Systematic Strategies LLC raised its position in Astria Therapeutics by 503.7% during the 1st quarter. Cubist Systematic Strategies LLC now owns 92,239 shares of the biotechnology company's stock worth $493,000 after purchasing an additional 76,961 shares during the last quarter. Finally, DAFNA Capital Management LLC raised its position in Astria Therapeutics by 5.0% during the 1st quarter. DAFNA Capital Management LLC now owns 314,775 shares of the biotechnology company's stock worth $1,681,000 after purchasing an additional 15,000 shares during the last quarter. Institutional investors and hedge funds own 98.98% of the company's stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.